Agenus presents data on agen1571 (anti-ilt2) at aacr and announces ind clearance

Lexington, mass., april 08, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, today announced the first presentation of preclinical data from agen1571 – a novel anti-ilt2 antibody designed to modulate tumor-associated macrophages, t, nk and nkt cells. these data are being presented at the american association for cancer research (aacr) annual meeting being held april 8-12 in new orleans, la.
AGEN Ratings Summary
AGEN Quant Ranking